Although short‐term intensive insulin therapy (SIIT) mitigates glucotoxicity, the effect of combining SIIT with sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in hospitalised type 2 diabetes mellitus (T2DM) patients with severe hyperglycemia remains unclear. This evidence concerns the gene SLC5A2 and Hyperglycemia.